CHD4 plays a critical role in arsenite-induced oxidative damage in human urothelial carcinoma
Related Experiment Video
Updated: Sep 11, 2026

Removal of Trace Elements by Cupric Oxide Nanoparticles from Uranium In Situ Recovery Bleed Water and Its Effect on Cell Viability
Published on: June 21, 2015
Shu-Jyuan Chang1, Pin-Jie Bin2, Chi-Wen Luo3
1Department of Pathology, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Pathology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
Abstract:
Inorganic arsenic (iAs), a known human carcinogen, induces oxidative DNA damage and epigenetic silencing of tumor suppressor genes related to tumor progression. Chromodomain-helicase-DNA-binding protein 4 (CHD4) is a chromatin remodeling protein that acts on DNA repair and DNA methylation under oxidative damage in malignancies, but the role of CHD4 in arsenical urothelial carcinoma (UC) is unidentified. Our purpose was to observe CHD4-related repair effects on As-stimulated oxidative damage in human UC. The markers of oxidative DNA damage 8-hydroxy-2'-deoxyguanosine (8-OHdG) and CHD4 were investigated by immunohistochemistry in 45 UC tissues from non-blackfoot disease (BFD) areas and BFD areas respectively. The cellular mechanisms of CHD4 involved in the oxidative DNA repair and DNA methylation were evaluated by immunocytochemistry and western blot. The expressions of CHD4 and 8-OHdG were significantly increased in UC patients from the As-exposed areas. The underlying mechanism of CHD4-mediated DNA repair and DNA methylation involved the activation of zinc finger MYND-type containing 8 (ZMYND8) and DNA methyltransferase (DNMTs) in SV-HUC-1, T24 and BFTC-905 cells. These results highlight the potential clinical significance of CHD4 in UCs from BFD areas. The CHD4-mediated oxidative DNA repair and epigenetic DNA methylation in UC cells stimulated by arsenic was revealed. CHD4 might be used as a prognostic indicator in arsenical UC.
Insights
Chromodomain-helicase-DNA-binding protein 4 (CHD4) plays a key role in repairing arsenic-induced DNA damage and regulating epigenetic changes in urothelial carcinoma (UC). Increased CHD4 expression is linked to arsenic exposure and may serve as a prognostic indicator for this cancer.
Area of Science:
- Oncology
- Molecular Biology
- Environmental Health
Background:
- Inorganic arsenic (iAs) is a human carcinogen causing oxidative DNA damage and epigenetic alterations.
- Chromodomain-helicase-DNA-binding protein 4 (CHD4) is involved in DNA repair and methylation under oxidative stress.
- The role of CHD4 in arsenical urothelial carcinoma (UC) remains unclear.
Purpose of the Study:
- To investigate CHD4's role in arsenic-induced oxidative DNA damage and repair mechanisms in human UC.
- To explore the clinical significance of CHD4 in UC patients from arsenic-exposed regions.
Main Methods:
- Immunohistochemistry was used to assess CHD4 and 8-hydroxy-2'-deoxyguanosine (8-OHdG) expression in 45 UC tissues.
- Immunocytochemistry and Western blot analyzed cellular mechanisms of CHD4 in DNA repair and methylation.
- Cell lines (SV-HUC-1, T24, BFTC-905) were used to study arsenic-stimulated effects.
Main Results:
- CHD4 and 8-OHdG expression were significantly elevated in UC patients from arsenic-exposed areas.
- CHD4-mediated DNA repair and methylation involved the activation of ZMYND8 and DNMTs.
- These findings reveal CHD4's involvement in arsenic-induced oxidative DNA damage and epigenetic modifications in UC cells.
Conclusions:
- CHD4 is implicated in the oxidative DNA repair and epigenetic DNA methylation processes in arsenic-stimulated UC cells.
- CHD4 may hold potential as a prognostic biomarker for arsenical urothelial carcinoma, particularly in Blackfoot Disease endemic areas.
More Related Videos
Related Concept Videos
Allosteric Proteins-ATCase
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
Bioactivation and Tissue Toxicity

